Major Estimate Revision • May 06
Consensus EPS estimates fall by 15% The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate fell from CN¥2.00 to CN¥1.71 per share. Revenue forecast steady at CN¥22.0b. Net income forecast to grow 4.5% next year vs 13% growth forecast for Healthcare industry in China. Consensus price target down from CN¥21.70 to CN¥21.08. Share price was steady at CN¥16.74 over the past week. Reported Earnings • May 01
First quarter 2026 earnings released: EPS: CN¥0.64 (vs CN¥0.70 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.64 (down from CN¥0.70 in 1Q 2025). Revenue: CN¥5.38b (up 1.1% from 1Q 2025). Net income: CN¥224.6m (down 19% from 1Q 2025). Profit margin: 4.2% (down from 5.2% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.4% p.a. on average during the next 2 years, compared to a 8.0% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 12% per year. Announcement • Apr 30
Guangxi LiuYao Group Co., Ltd, Annual General Meeting, May 20, 2026 Guangxi LiuYao Group Co., Ltd, Annual General Meeting, May 20, 2026, at 13:30 China Standard Time. Location: The Company's Meeting Room, Liuzhou, Guangxi China